IP Library Granted Patent US 11,129,975
Granted Patent B2
US 11,129,975 · App. 16/244,914 · Granted Sep 28, 2021

Transdermal delivery of high viscosity bioactive agents

Inventor: Russell F. Ross (Jacksonville Beach, FL)
Assignee: SORRENTO THERAPEUTICS, INC.
A61M37/0015A61K9/0021A61K31/167A61K31/485A61K31/5575A61K31/70A61K38/1808A61K38/191A61K38/20A61K38/21A61K38/26A61K38/28A61M2037/003A61M2037/0007A61M2037/0023A61M2037/0038A61M2037/0046A61M2037/0053A61M2037/0061
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,129,975
App. No.
16/244,914
Granted
Sep 28, 2021
Kind
B2
Abstract

A device and method for delivering a high viscosity composition is described. The composition includes a bioactive agent for delivery to a subject in need thereof. The method delivers the bioactive agent at a high bioavailability and with little loss of agent to the natural defense mechanisms of the body. The device includes one or more microneedles with structures fabricated on a surface of the microneedles to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes.

Claims (19)

1. A device for delivering a bioactive agent through a stratum corneum to a subdermal location of a user, the device comprising:

a microneedle having an exterior surface; and

a nanopatterned film disposed on the exterior surface of the microneedle, the nanopatterned film comprising:

a plurality of nanostructures, each nanostructure of the plurality of nanostructures having (i) a cross-sectional dimension less than about 500 nanometers and greater than about 5 nanometers and (ii) an aspect ratio from about 0.2 to about 5; and

a plurality of microstructures, each microstructure of the plurality of microstructures having (i) a cross-sectional dimension greater than about 500 nanometers and less than about 10 micrometers and (ii) an aspect ratio from about 0.15 to about 5.

2. The device of claim 1 wherein the plurality of nanostructures defines a plurality of first nanostructures, the device further comprising a plurality of second nanostructures, wherein each second nanostructure of the plurality of second nanostructures has a cross-sectional dimension less than the cross-sectional dimension of each microstructure of the plurality of microstructures and greater than the cross-sectional dimension of each nanostructure of the plurality of first nanostructures.

3. The device of claim 1 , wherein the exterior surface of the microneedle has an average surface roughness between about 10 nanometers and about 200 nanometers.

4. The device of claim 1 , wherein the exterior surface of the microneedle has an effective shear modulus between 4 MPa and 320 MPa.

5. The device of claim 1 , wherein each nanostructure of the plurality of nanostructures has a cross-sectional dimension from about 20 to about 400 nanometers, and wherein each microstructure of the plurality of microstructures has a cross-sectional dimension from about 600 nanometers to about 1.5 micrometers.

6. A device for delivering a bioactive agent through a stratum corneum to a subdermal location of a user, the device comprising:

a microneedle having an exterior surface; and

a nanopatterned film disposed on the exterior surface of the microneedle, the nanopatterned film comprising:

a plurality of first nanostructures, wherein each nanostructure of the plurality of first nanostructures has (i) a cross-sectional dimension less than about 500 nanometers and greater than about 5 nanometers and (ii) an aspect ratio from about 0.2 to about 5;

a plurality of second nanostructures, wherein each second nanostructure of the plurality of second nanostructures has a cross-sectional dimension greater than the cross-sectional dimension of each first nanostructure of the plurality of first nanostructures; and

a plurality of microstructures, wherein each microstructure of the plurality of microstructures has a cross-sectional dimension greater than (i) the cross-sectional dimension of each first nanostructure of the plurality of first nanostructures and (ii) the cross-sectional dimension of each second nanostructure of the plurality of second nanostructures.

7. The device of claim 6 , wherein each microstructure of the plurality of microstructures has (i) a cross-sectional dimension greater than about 500 nanometers and less than about 10 micrometers and (ii) a height from about 20 nanometers to about 1 micrometer.

8. The device of claim 6 , wherein the plurality of first nanostructures, the plurality of second nanostructures, and the plurality of microstructures are arranged to have a fractal dimension of about 2.5.

9. The device of claim 6 , wherein each second nanostructure of the plurality of second nanostructures defines a horizontal dimension that is about one third of a horizontal dimension corresponding to each microstructure of the plurality of microstructures.

10. The device of claim 6 , wherein each first nanostructure of the plurality of first nanostructures defines a horizontal dimension that is about one half of a horizontal dimension corresponding to each second nanostructure of the plurality of second nanostructures.

Assignments (6)
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: ROSS, RUSSELL F.
To: KIMBERLY-CLARK WORLDWIDE, INC.
Reel/Frame 047959/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: KIMBERLY-CLARK WORLDWIDE, INC.
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 047959/0460 →
Continuity (4)
Continuation 15411318 · Jan 20, 2017
Continuation 14354229
Provisional Application 61552069 · Oct 27, 2011
Related Publication 20190143092A1 · May 16, 2019
Cited By (1)
US 12,697,473